MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search

Articles tagged "Dystonia: Treatment"

  • 2017 International Congress

    Protocol for upper-limb kinematic analysis in paediatric movement disorders and relative normality data

    L. Garavaglia, E. Pagliano, A. Lo Mauro, G. Baranello, A. Aliverti, S. Pittaccio (Lecco, Italy)

    Objective: The study proposes a specialised protocol to collect and analyse kinematic data from paediatric patients affected by Movement Disorders (MD). The aim is to…
  • 2017 International Congress

    Clinical Relevance of Treatment With OnabotulinumtoxinA in Patients With Cervical Dystonia: Results From the CD Probe Study

    K. Dashtipour, Z. Mari, J. Jankovic, C. Adler, M. Schwartz, M. Brin (Loma Linda, CA, USA)

    Objective: To explore minimal clinically important change perceived by patients as beneficial by the Toronto Western Spasmodic Torticollis Rating Scale (TWSTRS) using data from the…
  • 2017 International Congress

    Design of a randomized, sham-controlled trial of pallidal neurostimulation versus botulinum toxin treatment for cervical dystonia (StimTox-CD)

    H. Drechsel, U. Malzahn, C. Roeser, P. Heuschmann, J. Volkmann (Würzburg, Germany)

    Objective: In this trial we will assess the efficacy and safety of pallidal deep brain stimulation (DBS) versus botulinum toxin A (BoNT A) therapy in cervical…
  • 2017 International Congress

    Oromandibular dystonia (OMD): A Prospective, Single-Blind Trial of AbobotulinumtoxinA (AboA)

    S. Factor, M. Silver, J. Hanfelt, E. Sperine, L. Scorr, A. Freeman, H. Jinnah (Atlanta, GA, USA)

    Objective: To examine the safety and efficacy of AboA in OMD Background: OMD causes involuntary movements of the lower facial, masticatory, and lingual muscles.  The…
  • 2017 International Congress

    Antibody-Induced Failure of Botulinum Toxin Therapy: Restart with Incobotulinumtoxina Offers a New Opportunity

    D. Dressler, F. Adib Saberi (Hamburg, Germany)

    Objective: To study whether incobotulinumtoxinA (INCO), a new, low-antigenicity botulinum toxin (BT) drug, increases BT antibody (BTAB) titers in patients with antibody-induced therapy failure (ABTF)…
  • 2017 International Congress

    Prevelance,clinical pathology and Treatment of Dystonia in Pakistani Population

    S. Naureen, A. Arshad, N. Ahmad (RAWALPINDI, Pakistan)

    Objective:  Evaluate the gender,mean age,clinical spectrum and non–motor symptoms of the disease in Pakistan,a developing country of South East Asia. Background: Dystonia,a neurological syndrome,is characterized…
  • 2017 International Congress

    Onabotulinumtoxin A (Botox) displays superior activity to incobotulinumtoxinA (Xeomin) in multiple in vitro and in vivo assays

    D. Canty, L. Le, J. Wang, G. Nicholson, A. Brideau-Andersen, L. Steward, B. Jacky, R. Broide, M. Washburn, D. Rupp (Irvine, CA, USA)

    Objective: This study was conducted to assess in vivo and in vitro activity of 50 U, 100 U, and 200 U vials of incobotulinumtoxinA (Merz,…
  • 2017 International Congress

    Clinical analysis of patients with servical dystonia who Botulinum toxin injection is performed: 10 years experience of Ege University Neurology Department of Movement Disorders Clinic

    A. Acarer, S. Ciftci, Z. Colakoglu (Izmir, Turkey)

    Objective: In this study, it is aimed to analysis of clinical features and  treatment efficiency  in patients with servical dystonia who are performed Botulinum injection…
  • 2017 International Congress

    Efficacy and Safety of a 2 mL Dilution of AbobotulinumtoxinA Compared With Placebo in Adult Patients With Cervical Dystonia

    M. Lew, D. Snyder (Los Angeles, CA, USA)

    Objective: To determine the efficacy and safety of a 500 U/2 mL dilution of aboBoNT-A as compared to placebo in patients with cervical dystonia (CD).…
  • 2017 International Congress

    Cognitive Function is Preserved 10 Years Following DBS in People with Dystonia

    E. Hogg, J. Eskenazi, E. During, J. Wertheimer, R. Alterman, M. Tagliati (Los Angeles, CA, USA)

    Objective: To study cognitive function in people with dystonia chronically treated with Deep Brain Stimulation (DBS). Background: The impact of DBS on cognition is a matter of…
  • « Previous Page
  • 1
  • …
  • 25
  • 26
  • 27
  • 28
  • 29
  • …
  • 35
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Life expectancy with and without Parkinson’s disease in the general population
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Patients with Essential Tremor Live Longer than their Relatives
  • An atypical and interesting feature of Parkinson´s disease
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • Life expectancy with and without Parkinson’s disease in the general population
  • The hardest symptoms that bother patients with Parkinson's disease
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley